Politics & Law
ProPublica Prompts GAO Investigation of FDA
Sens. Dick Durbin and Richard Blumenthal asked the Government Accountability Office to investigate the Food and Drug Administration.
Read more
Politics & Business of Drug Imports
The Food and Drug Administration's approval of Florida’s plan to import drugs was made possible after Alex Azar certified it.
Read more
An Impossible Choice
Is a doctor allowed to protect a patient's life when politicians believe the patient should be allowed to die?
Read more
DEA Comments Gaffe
The DEA (Drug Enforcement Agency) has ordained its decree: Another year, another decrease in the production quota for prescription opioids.
Read more
Mental Health Courts Struggle to Fulfill Mission
Advocates, attorneys, clinicians, and researchers say mental health courts struggle to live up to their promise.
Read more
Physicians: Write Legal Briefs
In recent years, there has been an increasing need for physicians to participate in complex healthcare legal cases by writing...
Read more
Opioid Settlements: “Cash Cow”
“It’s heartbreaking to see what the government is doing with this money. Putting it in places they really don’t need...
Read more
Black Swans of Health Policy
Don’t worry about the healthcare laws. Worry about the changing legal interpretations of existing healthcare laws.
Read more
Gun Education is Harm Reduction
As a former marine and emergency medicine physician, I bring a unique perspective on gun control and ownership.
Read more
We May Soon Have a Nitazene Crisis
A drug testing service reported that, since September, nitazenes were found in 20 samples of black market benzodiazepines.
Read more
Addiction Isn’t Just Genetic
The impact of behavioral factors on addiction is a complex and multifaceted topic that continues to be researched and explored.
Read more
Abortion: Harbinger of Healthcare
We saw two major cases on abortion this week. Unfortunately, this feels like a harbinger of things to come.
Read more
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more